Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success in Healthcare Conference 2017
December 06 2017 - 8:00AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage
biopharmaceutical company developing novel antibiotics to treat
life-threatening multidrug-resistant (MDR) infections, today
announced that company management will participate in a fireside
chat discussion at the BMO Capital Markets 2017 Prescriptions for
Success in Healthcare Conference on Thursday, December 14 at 4:00
p.m. Eastern Time at the Westin New York Grand Central Hotel in New
York City.
Live audio webcasts of the presentation will be
available on the company’s website at
http://ir.tphase.com/events.cfm. Archived presentations will be
available for 30 days.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a clinical-stage biopharmaceutical
company using its proprietary chemistry technology to create novel
antibiotics for serious and life-threatening bacterial infections,
including those caused by many of the multidrug-resistant (MDR)
bacteria highlighted as urgent public health threats by the CDC.
Tetraphase has created more than 3,000 novel tetracycline analogs
using its proprietary technology platform. Tetraphase's pipeline
includes three antibiotic clinical candidates: eravacycline, which
is in phase 3 clinical trials, and TP-271 and TP-6076, which are in
phase 1 clinical trials. Please visit www.tphase.com for more
company information.
Investor Contact:Argot PartnersMaeve
Conneighton206-899-4940maeve@argotpartners.com
Media Contact:Sam Brown Inc.Mike
Beyer312-961-2502mikebeyer@sambrown.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024